@Tim_Corr Avatar @Tim_Corr Tim

Tim posts on X about $qure, in the, can you, lack of the most. They currently have [---] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [---] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social topic influence $qure #2, in the 14.29%, can you 7.14%, lack of 7.14%, $rgnx 7.14%, fda 7.14%, the new 7.14%, this is 7.14%, the world 7.14%, level 7.14%

Top accounts mentioned or mentioned by @unknowntester @canoebrookbl @hawkking1515 @mike98572986 @biotechautist @petermantas

Top assets mentioned uniQure N.V. (QURE)

Top Social Posts

Top posts by engagements in the last [--] hours

"https://open.substack.com/pub/backofthenapkinbios/p/how-rgnx-got-qured-a-regulatory-regimer=2fri1p&utm_medium=ios https://open.substack.com/pub/backofthenapkinbios/p/how-rgnx-got-qured-a-regulatory-regimer=2fri1p&utm_medium=ios"
X Link 2026-02-10T10:25Z [---] followers, [---] engagements

"@unknown_tester_ @canoebrookbl Can you share that note where Matt called MM his guy"
X Link 2026-02-14T02:18Z [---] followers, [---] engagements

"The tell in the Moderna decision wasnt the rejection - it was the lack of a roadmap. FDA gives fixes when it sees a path ( $RGNX $QURE) silence is deliberate doctrine-setting under Makary/Prasad"
X Link 2026-02-11T03:06Z [---] followers, [---] engagements

"This is why FDA engagement with $QURE matters. Type A meetings are about how not whether. Under the new doctrine: clinical outcomes first surrogates as support context over platforms. Silence vs engagement is the signal"
X Link 2026-02-11T03:12Z [---] followers, [---] engagements

"$QURE One point I believe the market may be underpricing is how robust the CHDI Enroll HD data is"
X Link 2026-02-14T16:33Z [---] followers, [----] engagements

"$QURE ENROLL-HD is the largest longitudinal HD dataset in the world designed specifically to model disease progression and support trial endpoints. Very few rare diseases have this level of scientific depth behind them"
X Link 2026-02-14T16:33Z [---] followers, [----] engagements

"$QURE A robust external control reduces counterfactual uncertainty which strengthens the statistical weight of observed clinical separation"
X Link 2026-02-14T16:38Z [---] followers, [---] engagements

"Nine days later Makary + Prasad published the NEJM plausible mechanism pathwaya framework built for monogenic diseases where placebo controls arent feasible and external controls are standard. AMT-130 fits this structure almost exactly. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [----] engagements

"@hawkking1515 @mike98572986 $QURE"
X Link 2025-11-15T15:17Z [---] followers, [---] engagements

"@BiotechAutist Great thread. Thanks for your insight and analysis. I believe FDA's decision on this will be the barometer for $QURE and amt-130"
X Link 2026-01-16T15:00Z [--] followers, [---] engagements

"The market read Nov [--] as a failure but the broader sequence points to regulatory repositioning not FDA walking away. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [---] engagements

"UniQures Nov [--] FDA setback on AMT-130 looks more like a procedural reset than a scientific rejection. FDA said the external control approach was no longer adequate despite no new data. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [----] engagements

"UniQures language (currently no longer agrees timely accelerated approval path forward) and the absence of new safety/efficacy concerns support this. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [---] engagements

"RT @peter_mantas: I want to be very clear about this re: $QURE. The only people still debating whether AMT-130 is approvable are investors"
X Link 2026-01-20T19:28Z [---] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing